Small molecule KDM4s inhibitors as anti-cancer agents

References

• Andreoli F, Barbosa AJ, Parenti MD, et al. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des 2013;19:578–613.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu K, Qin S, et al. Epigenetic targets and drug discovery: Part 1: histone methylation. Pharmacol Ther 2014;143:275–94.
   PubMed Web of Science ®Google Scholar
• Liu K, Liu Y, Lau JL, et al. Epigenetic targets and drug discovery. Part 2: histone demethylation and DNA methylation. Pharmacol Ther 2015;151:121–40.
   PubMed Web of Science ®Google Scholar
• New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code?. Mol Oncol 2012;6:637–56.
   PubMed Web of Science ®Google Scholar
• Lee J, Huang RS. Cancer epigenetics: mechanisms and crosstalk of a HDAC inhibitor, vorinostat. Chemotherapy 2013;2:111. doi: 10.4172/2167-7700.1000111
   Google Scholar
• Srinivas NR. Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives. Xenobiotica 2016;1–15:354–368.
   Google Scholar
• Yoon S, Eom GH. HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam Med J 2016;52:1–11.
   PubMedGoogle Scholar
• Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004;14:R546–51.
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074–80.
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693–705.
   PubMed Web of Science ®Google Scholar
• Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012;13:343–57.
   PubMed Web of Science ®Google Scholar
• Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005;74:481–514.
   PubMed Web of Science ®Google Scholar
• Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004;119:941–53.
   PubMed Web of Science ®Google Scholar
• Tsukada Y, Fang J, Erdjument-Bromage H, et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006;439:811–6.
   PubMed Web of Science ®Google Scholar
• Guerra-Calderas L, Gonzalez-Barrios R, Herrera LA, et al. The role of the histone demethylase KDM4A in cancer. Cancer Genet 2015;208:215–24.
   PubMed Web of Science ®Google Scholar
• Berry WL, Janknecht R. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res 2013;73:2936–42.
   PubMed Web of Science ®Google Scholar
• Rotili D, Mai A. Targeting histone demethylases: a new avenue for the fight against cancer. Genes Cancer 2011;2:663–79.
   PubMedGoogle Scholar
• Katoh M, Katoh M. Identification and characterization of JMJD2 family genes in silico. Int J Oncol 2004;24:1623–8.
   PubMed Web of Science ®Google Scholar
• Chu CH, Wang LY, Hsu KC, et al. KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor. J Med Chem 2014;57:5975–85.
   PubMed Web of Science ®Google Scholar
• Kawazu M, Saso K, Tong KI, et al. Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One 2011;6:e17830.
   PubMed Web of Science ®Google Scholar
• Berry WL, Shin S, Lightfoot SA, et al. Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int J Oncol 2012;41:1701–6.
   PubMed Web of Science ®Google Scholar
• Kim TD, Shin S, Berry WL, et al. The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem 2012;113:1368–76.
   PubMed Web of Science ®Google Scholar
• Lohse B, Kristensen JL, Kristensen LH, et al. Inhibitors of histone demethylases. Bioorg Med Chem 2011;19:3625–36.
   PubMed Web of Science ®Google Scholar
• Rose NR, Mcdonough MA, King ON, et al. Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev 2011;40:4364–97.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Miyata N. Lysine demethylases inhibitors. J Med Chem 2011;54:8236–50.
   PubMed Web of Science ®Google Scholar
• Lillico R, Stesco N, Khorshid Amhad T, et al. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity. Future Med Chem 2016;8:879–97.
   PubMed Web of Science ®Google Scholar
• Mcallister TE, England KS, Hopkinson RJ, et al. Recent progress in histone demethylase inhibitors. J Med Chem 2016;59:1308–29.
   PubMed Web of Science ®Google Scholar
• Nowak RP, Tumber A, Johansson C, et al. Advances and challenges in understanding histone demethylase biology. Curr Opin Chem Biol 2016;33:151–9.
   PubMed Web of Science ®Google Scholar
• Maes T, Carceller E, Salas J, et al. Advances in the development of histone lysine demethylase inhibitors. Curr Opin Pharmacol 2015;23:52–60.
   PubMed Web of Science ®Google Scholar
• Whetstine JR, Nottke A, Lan F, et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 2006;125:467–81.
   PubMed Web of Science ®Google Scholar
• Trojer P, Zhang J, Yonezawa M, et al. Dynamic histone H1 isotype 4 methylation and demethylation by histone lysine methyltransferase G9a/KMT1C and the Jumonji domain-containing JMJD2/KDM4 proteins. J Biol Chem 2009;284:8395–405.
   PubMed Web of Science ®Google Scholar
• Nakayama J, Rice JC, Strahl BD, et al. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 2001;292:110–3.
   PubMed Web of Science ®Google Scholar
• Peters AH, Mermoud JE, O’Carroll D, et al. Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nat Genet 2002;30:77–80.
   PubMed Web of Science ®Google Scholar
• Gilbert TM, Mcdaniel SL, Byrum SD, et al. A PWWP domain-containing protein targets the NuA3 acetyltransferase complex via histone H3 lysine 36 trimethylation to coordinate transcriptional elongation at coding regions. Mol Cell Proteomics 2014;13:2883–95.
   PubMed Web of Science ®Google Scholar
• Kizer KO, Phatnani HP, Shibata Y, et al. A novel domain in Set2 mediates RNA polymerase II interaction and couples histone H3 K36 methylation with transcript elongation. Mol Cell Biol 2005;25:3305–16.
   PubMed Web of Science ®Google Scholar
• Hu CE, Liu YC, Zhang HD, et al. JMJD2A predicts prognosis and regulates cell growth in human gastric cancer. Biochem Biophys Res Commun 2014;449:1–7.
   PubMed Web of Science ®Google Scholar
• Gray SG, Iglesias AH, Lizcano F, et al. Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein. J Biol Chem 2005;280:28507–18.
   PubMed Web of Science ®Google Scholar
• Hopkinson RJ, Walport LJ, Munzel M, et al. Is JmjC oxygenase catalysis limited to demethylation?. Angew Chem Int Ed Engl 2013;52:7709–13.
   PubMed Web of Science ®Google Scholar
• Black JC, Allen A, Van Rechem C, et al. Conserved antagonism between JMJD2A/KDM4A and HP1γ during cell cycle progression. Mol Cell 2010;40:736–48.
   PubMed Web of Science ®Google Scholar
• Shin S, Janknecht R. Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun 2007;359:742–6.
   PubMed Web of Science ®Google Scholar
• Wissmann M, Yin N, Muller JM, et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 2007;9:347–53.
   PubMed Web of Science ®Google Scholar
• Coffey K, Rogerson L, Ryan-Munden C, et al. The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. Nucleic Acids Res 2013;41:4433–46.
   PubMed Web of Science ®Google Scholar
• Qiu MT, Fan Q, Zhu Z, et al. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1. Oncotarget 2015;6:31702–20.
   PubMedGoogle Scholar
• Li BX, Zhang MC, Luo CL, et al. Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro. J Exp Clin Cancer Res 2011;30:90.
   PubMed Web of Science ®Google Scholar
• Li BX, Luo CL, Li H, et al. Effects of siRNA-mediated knockdown of jumonji domain containing 2A on proliferation, migration and invasion of the human breast cancer cell line MCF-7. Exp Ther Med 2012;4:755–61.
   PubMed Web of Science ®Google Scholar
• Li L, Gao P, Li Y, et al. JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3. Breast Cancer Res Treat 2014;147:487–500.
   PubMed Web of Science ®Google Scholar
• Kauffman EC, Robinson BD, Downes MJ, et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 2011;50:931–44.
   PubMed Web of Science ®Google Scholar
• Johmura Y, Sun J, Kitagawa K, et al. SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates senescence. Nat Commun 2016;7:10574.
   PubMed Web of Science ®Google Scholar
• Tan MK, Lim HJ, Harper JW. SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation. Mol Cell Biol 2011;31:3687–99.
   PubMed Web of Science ®Google Scholar
• Van Rechem C, Black JC, Abbas T, et al. The SKP1-Cul1-F-box and leucine-rich repeat protein 4 (SCF-FbxL4) ubiquitin ligase regulates lysine demethylase 4A (KDM4A)/Jumonji domain-containing 2A (JMJD2A) protein. J Biol Chem 2011;286:30462–70.
   PubMed Web of Science ®Google Scholar
• Mallette FA, Richard S. JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. Cell Rep 2012;2:1233–43.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, De Lange T. 53BP1: pro choice in DNA repair. Trends Cell Biol 2014;24:108–17.
   PubMed Web of Science ®Google Scholar
• Mallette FA, Mattiroli F, Cui G, et al. RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J 2012;31:1865–78.
   PubMed Web of Science ®Google Scholar
• Das A, Chai JC, Jung KH, et al. JMJD2A attenuation affects cell cycle and tumourigenic inflammatory gene regulation in lipopolysaccharide stimulated neuroectodermal stem cells. Exp Cell Res 2014;328:361–78.
   PubMed Web of Science ®Google Scholar
• Chang PC, Fitzgerald LD, Hsia DA, et al. Histone demethylase JMJD2A regulates Kaposi’s sarcoma-associated herpesvirus replication and is targeted by a viral transcriptional factor. J Virol 2011;85:3283–93.
   PubMed Web of Science ®Google Scholar
• Das ND, Choi MR, Jung KH, et al. Functional analysis of histone demethylase Jmjd2b on lipopolysaccharide-treated murine neural stem cells (NSCs). Neurotox Res 2013;23:154–65.
   PubMed Web of Science ®Google Scholar
• Antony J, Oback F, Chamley LW, et al. Transient JMJD2B-mediated reduction of H3K9me3 levels improves reprogramming of embryonic stem cells into cloned embryos. Mol Cell Biol 2013;33:974–83.
   PubMed Web of Science ®Google Scholar
• Shi L, Sun L, Li Q, et al. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci USA 2011;108:7541–6.
   PubMed Web of Science ®Google Scholar
• Kim JG, Yi JM, Park SJ, et al. Histone demethylase JMJD2B-mediated cell proliferation regulated by hypoxia and radiation in gastric cancer cell. Biochim Biophys Acta 2012;1819:1200–7.
   PubMed Web of Science ®Google Scholar
• Li W, Zhao L, Zang W, et al. Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer. Biochem Biophys Res Commun 2011;416:372–8.
   PubMed Web of Science ®Google Scholar
• Zhao L, Li W, Zang W, et al. JMJD2B promotes epithelial-mesenchymal transition by cooperating with beta-catenin and enhances gastric cancer metastasis. Clin Cancer Res 2013;19:6419–29.
   PubMed Web of Science ®Google Scholar
• Berry WL, Kim TD, Janknecht R. Stimulation of β-catenin and colon cancer cell growth by the KDM4B histone demethylase. Int J Oncol 2014;44:1341–8.
   PubMed Web of Science ®Google Scholar
• Cloos PA, Christensen J, Agger K, et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006;442:307–11.
   PubMed Web of Science ®Google Scholar
• Luo W, Chang R, Zhong J, et al. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci USA 2012;109:E3367–76.
   PubMed Web of Science ®Google Scholar
• Ishimura A, Terashima M, Kimura H, et al. Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene. Biochem Biophys Res Commun 2009;389:366–71.
   PubMed Web of Science ®Google Scholar
• Farooq Z, Banday S, Pandita TK, et al. The many faces of histone H3K79 methylation. Mutat Res Rev Mutat Res 2016;768:46–52.
   PubMed Web of Science ®Google Scholar
• Jbara M, Guttmann-Raviv N, Maity SK, et al. Total chemical synthesis of methylated analogues of histone 3 revealed KDM4D as a potential regulator of H3K79me3. Bioorg Med Chem 2017;25:4966–70.
   PubMed Web of Science ®Google Scholar
• Huang F, Chandrasekharan MB, Chen YC, et al. The JmjN domain of Jhd2 is important for its protein stability, and the plant homeodomain (PHD) finger mediates its chromatin association independent of H3K4 methylation. J Biol Chem 2010;285:24548–61.
   PubMed Web of Science ®Google Scholar
• Ozboyaci M, Gursoy A, Erman B, et al. Molecular recognition of H3/H4 histone tails by the tudor domains of JMJD2A: a comparative molecular dynamics simulations study. PLoS One 2011;6:e14765.
   PubMed Web of Science ®Google Scholar
• Schofield CJ, Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr Opin Struct Biol 1999;9:722–31.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zang J, Whetstine J, et al. Structural insights into histone demethylation by JMJD2 family members. Cell 2006;125:691–702.
   PubMed Web of Science ®Google Scholar
• Clifton IJ, Mcdonough MA, Ehrismann D, et al. Structural studies on 2-oxoglutarate oxygenases and related double-stranded beta-helix fold proteins. J Inorg Biochem 2006;100:644–69.
   PubMed Web of Science ®Google Scholar
• Ng SS, Kavanagh KL, Mcdonough MA, et al. Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity. Nature 2007;448:87–91.
   PubMed Web of Science ®Google Scholar
• Williams ST, Walport LJ, Hopkinson RJ, et al. Studies on the catalytic domains of multiple JmjC oxygenases using peptide substrates. Epigenetics 2014;9:1596–603.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Trievel RC. Structural and functional analysis of JMJD2D reveals molecular basis for site-specific demethylation among JMJD2 demethylases. Structure 2013;21:98–108.
   PubMed Web of Science ®Google Scholar
• Smith EH, Janknecht R, Maher LJ 3rd. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet 2007;16:3136–48.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011;12:463–9.
   PubMed Web of Science ®Google Scholar
• Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009;324:261–5.
   PubMed Web of Science ®Google Scholar
• Rose NR, Ng SS, Mecinovic J, et al. Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. J Med Chem 2008;51:7053–6.
   PubMed Web of Science ®Google Scholar
• Rose NR, Woon EC, Kingham GL, et al. Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches. J Med Chem 2010;53:1810–8.
   PubMed Web of Science ®Google Scholar
• Hamada S, Suzuki T, Mino K, et al. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of Jumonji domain-containing protein 2 histone demethylase inhibitors. J Med Chem 2010;53:5629–38.
   PubMed Web of Science ®Google Scholar
• Rose NR, Woon ECY, Tumber A, et al. Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J Med Chem 2012;55:6639–43.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ozasa H, Itoh Y, et al. Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity. J Med Chem 2013;56:7222–31.
   PubMed Web of Science ®Google Scholar
• Itoh Y, Sawada H, Suzuki M, et al. Identification of Jumonji AT-rich interactive domain 1A inhibitors and their effect on cancer cells. ACS Med Chem Lett 2015;6:665–70.
   PubMed Web of Science ®Google Scholar
• Morera L, Roatsch M, Furst MC, et al. 4-Biphenylalanine- and 3-phenyltyrosine-derived hydroxamic acids as inhibitors of the JumonjiC-domain-containing histone demethylase KDM4A. ChemMedChem 2016;11:2063–83.
   PubMed Web of Science ®Google Scholar
• Luo XL, Liu YX, Kubicek S, et al. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J Am Chem Soc 2011;133:9451–6.
   PubMed Web of Science ®Google Scholar
• King ON, Li XS, Sakurai M, et al. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS One 2010;5:e15535.
   PubMed Web of Science ®Google Scholar
• Hopkinson RJ, Tumber A, Yapp C, et al. 5-Carboxy-8-hydroxyquinoline is a broad spectrum 2-oxoglutarate oxygenase inhibitor which causes iron translocation. Chem Sci 2013;4:3110–7.
   PubMed Web of Science ®Google Scholar
• Feng T, Li D, Wang H, et al. Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: introduction of an additional carboxyl group at the C-2 position of quinoline. Eur J Med Chem 2015;105:145–55.
   PubMed Web of Science ®Google Scholar
• Duan L, Rai G, Roggero C, et al. KDM4/JMJD2 histone demethylase inhibitors block prostate tumor growth by suppressing the expression of AR and BMYB-regulated genes. Chem Biol 2015;22:1185–96.
   PubMedGoogle Scholar
• Thinnes CC, Tumber A, Yapp C, et al. Betti reaction enables efficient synthesis of 8-hydroxyquinoline inhibitors of 2-oxoglutarate oxygenases. Chem Commun (Camb) 2015;51:15458–61.
   PubMed Web of Science ®Google Scholar
• Schiller R, Scozzafava G, Tumber A, et al. A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. ChemMedChem 2014;9:566–71.
   PubMed Web of Science ®Google Scholar
• Carter DM, Specker E, Przygodda J, et al. Identification of a novel benzimidazole pyrazolone scaffold that inhibits KDM4 lysine demethylases and reduces proliferation of prostate cancer cells. SLAS Discov 2017;22:801–12.
   PubMed Web of Science ®Google Scholar
• Thalhammer A, Mecinovic J, Loenarz C, et al. Inhibition of the histone demethylase JMJD2E by 3-substituted pyridine 2,4-dicarboxylates. Org Biomol Chem 2011;9:127–35.
   PubMed Web of Science ®Google Scholar
• Wang L, Chang J, Varghese D, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun 2013;4:2035.
   PubMed Web of Science ®Google Scholar
• Roatsch M, Robaa D, Pippel M, et al. Substituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylases. Future Med Chem 2016;8:1553–71.
   PubMed Web of Science ®Google Scholar
• England KS, Tumber A, Krojer T, et al. Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor. Medchemcomm 2014;5:1879–86.
   PubMed Web of Science ®Google Scholar
• Bavetsias V, Lanigan RM, Ruda GF, et al. 8-Substituted pyrido[3,4-d]pyrimidin-4(3H)-one derivatives as potent, cell permeable, KDM4 (JMJD2) and KDM5 (JARID1) histone lysine demethylase inhibitors. J Med Chem 2016;59:1388–409.
   PubMed Web of Science ®Google Scholar
• Westaway SM, Preston AG, Barker MD, et al. Cell penetrant inhibitors of the KDM4 and KDM5 families of histone lysine demethylases. 1. 3-Amino-4-pyridine carboxylate derivatives. J Med Chem 2016;59:1357–69.
   PubMed Web of Science ®Google Scholar
• Westaway SM, Preston AG, Barker MD, et al. Cell penetrant inhibitors of the KDM4 and KDM5 families of histone lysine demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one derivatives. J Med Chem 2016;59:1370–87.
   PubMed Web of Science ®Google Scholar
• Fang Z, Wang TQ, Li H, et al. Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors. Bioorg Med Chem Lett 2017;27:3201–4.
   PubMed Web of Science ®Google Scholar
• Chen YK, Bonaldi T, Cuomo A, et al. Design of KDM4 inhibitors with antiproliferative effects in cancer models. ACS Med Chem Lett 2017;8:869–74.
   PubMed Web of Science ®Google Scholar
• Metzger E, Stepputtis SS, Strietz J, et al. KDM4 inhibition targets breast cancer stem-like cells. Cancer Res 2017;77:5900–12.
   PubMed Web of Science ®Google Scholar
• Korczynska M, Le DD, Younger N, et al. Docking and linking of fragments to discover Jumonji histone demethylase inhibitors. J Med Chem 2016;59:1580–98.
   PubMed Web of Science ®Google Scholar
• Xu W, Podoll JD, Dong X, et al. Quantitative analysis of histone demethylase probes using fluorescence polarization. J Med Chem 2013;56:5198–202.
   PubMed Web of Science ®Google Scholar
• Wang W, Marholz LJ, Wang X. Novel scaffolds of cell-active histone demethylase inhibitors identified from high-throughput screening. J Biomol Screen 2015;20:821–7.
   PubMedGoogle Scholar
• Sakurai M, Rose NR, Schultz L, et al. A miniaturized screen for inhibitors of Jumonji histone demethylases. Mol BioSyst 2010;6:357.
   PubMed Web of Science ®Google Scholar
• Feng T, Chen W, Li D, et al. Identification of novel JMJD2A inhibitor scaffold using shape and electrostatic similarity search combined with docking method and MM-GBSA approach. RSC Adv 2015;5(101):82936–46.
   Web of Science ®Google Scholar
• Kim TD, Fuchs JR, Schwartz E, et al. Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors. Am J Transl Res 2014;6:236–47.
   PubMed Web of Science ®Google Scholar
• Baell J, Walters MA. Chemistry: chemical con artists foil drug discovery. Nature 2014;513:481–3.
   PubMed Web of Science ®Google Scholar
• Sekirnik R, Rose NR, Thalhammer A, et al. Inhibition of the histone lysine demethylase JMJD2A by ejection of structural Zn(II). Chem Commun (Camb) 2009;6376–8.
   PubMed Web of Science ®Google Scholar
• Chen HB, Kluz T, Zhang RH, et al. Hypoxia and nickel inhibit histone demethylase JMJD1A and repress Spry2 expression in human bronchial epithelial BEAS-2B cells. Carcinogenesis 2010;31:2136–44.
   PubMed Web of Science ®Google Scholar
• Liu LJ, Lu L, Zhong HJ, et al. An iridium(III) complex inhibits JMJD2 activities and acts as a potential epigenetic modulator. J Med Chem 2015;58:6697–703.
   PubMed Web of Science ®Google Scholar
• Lohse B, Nielsen AL, Kristensen JB, et al. Targeting histone lysine demethylases by truncating the histone 3 tail to obtain selective substrate-based inhibitors. Angew Chem Int Ed Engl 2011;50:9100–3.
   PubMed Web of Science ®Google Scholar
• Woon EC, Tumber A, Kawamura A, et al. Linking of 2-oxoglutarate and substrate binding sites enables potent and highly selective inhibition of JmjC histone demethylases. Angew Chem Int Ed Engl 2012;51:1631–4.
   PubMed Web of Science ®Google Scholar
• Leurs U, Lohse B, Rand KD, et al. Substrate- and cofactor-independent inhibition of histone demethylase KDM4C. ACS Chem Biol 2014;9:2131–8.
   PubMed Web of Science ®Google Scholar
• Kawamura A, Munzel M, Kojima T, et al. Highly selective inhibition of histone demethylases by de novo macrocyclic peptides. Nat Commun 2017;8:14773.
   PubMed Web of Science ®Google Scholar
• Pilka ES, James T, Lisztwan JH. Structural definitions of Jumonji family demethylase selectivity. Drug Discov Today 2015;20:743–9.
   PubMed Web of Science ®Google Scholar
• Rasmussen PB, Staller P. The KDM5 family of histone demethylases as targets in oncology drug discovery. Epigenomics 2014;6:277–86.
   PubMed Web of Science ®Google Scholar
• Horton JR, Liu X, Gale M, et al. Structural basis for KDM5A histone lysine demethylase inhibition by diverse compounds. Cell Chem Biol 2016;23:769–81.
   PubMed Web of Science ®Google Scholar
• Rotili D, Mattevi A. At long last potent and selective KDM5 inhibitors. Cell Chem Biol 2016;23:749–51.
   PubMed Web of Science ®Google Scholar
• Hatch SB, Yapp C, Montenegro RC, et al. Assessing histone demethylase inhibitors in cells: lessons learned. Epigenet Chromatin 2017;10:9.
   PubMed Web of Science ®Google Scholar
• Tumber A, Nuzzi A, Hookway ES, et al. Potent and selective KDM5 inhibitor stops cellular demethylation of H3K4me3 at transcription start sites and proliferation of MM1S myeloma cells. Cell Chem Biol 2017;24:371–80.
   PubMed Web of Science ®Google Scholar
• Gale M, Sayegh J, Cao J, et al. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance. Oncotarget 2016;7:39931–44.
   PubMedGoogle Scholar
• Gehling VS, Bellon SF, Harmange JC, et al. Identification of potent, selective KDM5 inhibitors. Bioorg Med Chem Lett 2016;26:4350–4.
   PubMed Web of Science ®Google Scholar
• Liang J, Zhang B, Labadie S, et al. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies. Bioorg Med Chem Lett 2016;26:4036–41.
   PubMed Web of Science ®Google Scholar
• Labadie SS, Dragovich PS, Cummings RT, et al. Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors. Bioorg Med Chem Lett 2016;26:4492–6.
   PubMed Web of Science ®Google Scholar
• Liang J, Labadie S, Zhang B, et al. From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors. Bioorg Med Chem Lett 2017;27:2974–81.
   PubMed Web of Science ®Google Scholar
• Kruidenier L, Chung CW, Cheng Z, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012;488:404–8.
   PubMed Web of Science ®Google Scholar
• Hu J, Wang X, Chen L, et al. Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors. Bioorg Med Chem Lett 2016;26:721–5.
   PubMed Web of Science ®Google Scholar
• Henikoff S, Shilatifard A. Histone modification: cause or cog?. Trends Genet 2011;27:389–96.
   PubMed Web of Science ®Google Scholar
• Chin YW, Han SY. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review. Expert Opin Ther Pat 2015;25:135–44.
   PubMed Web of Science ®Google Scholar